 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Biotechnology Industry Organization (BIO)
|
-
BIO Commemorates the 25th Anniversary of the Orphan Drug Act
(01/08/2008)
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement commemorating the 25th anniversary of the Orphan Drug Act. This landmark law helped lead to the development of new drugs and biologics for rare ...
-
BIO Supports Bill to Modernize the Tax Code for Life Sciences Companies
(08/07/2007)
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), thanked U.S. Representatives Allyson Schwartz (D-PA) and Kevin Brady (R-TX) for their leadership in introducing the American Life Sciences Competitiveness Act of 2007 ...
-
BIO White Paper Dispels Over-Patenting Myth
(06/04/2007)
Patenting is a Critical Element in Fostering Research and Development
The theory claiming that the over-patenting of biotechnology research hinders the research and development of new treatments is not supported by empirical evidence, concludes a white paper entitled "The Myth of the Anticommons" released by the ...
-
BIO Urges Congress to Allow More Companies to Compete for SBIR Grants
(04/30/2007)
More Competition Would Allow Funding of Better Science
Dr. Gary McGarrity, Executive Vice President of Scientific and Clinical Affairs at VIRxSYS, testified on behalf of the Biotechnology Industry Organization (BIO) before the House Science and Technology Subcommittee on Technology and Innovation ...
-
BIO expresses concerns regarding new patent reform legislation
(04/20/2007)
he following statement was issued by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood regarding the Patent Reform Act of 2007, introduced by Senators Patrick Leahy (D-VT) and Orrin Hatch (R-UT) and Congressmen Howard Berman ...
-
BIO Establishes New Headquarters
(04/13/2007)
Earlier this week, the Biotechnology Industry Organization (BIO) relocated their headquarters to Southwest Washington, D.C."This new location meets the needs of our growing organization," stated BIO President and CEO Jim Greenwood. "Our growth ...
-
New Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs
(04/12/2007)
The widening use of new, innovative biopharmaceutical treatments for diseases, such as cancer, multiple sclerosis and heart disease, will have a limited impact on healthcare costs for private healthcare payers over the next several years, according ...
-
Pfizer's Kindler Joins BIO Board of Directors
(02/22/2007)
The Biotechnology Industry Organization (BIO) announced the election of Pfizer Chairman and CEO Jeffrey B. Kindler to BIO's Board of Directors. Kindler will replace Pfizer Vice President of Corporate Policy and Strategic Management Fred Telling, who ...
-
BIO Urges Congress to Further Increase FDA Budget
(02/13/2007)
Commends President for Proposed Funding Increases to FDA, Pandemic Preparedness and Biodefense Countermeasures
The Biotechnology Industry Organization (BIO) praised the proposed budget for FY2008 announced by President Bush as a good starting point and urged Congress to further increase funding for the Food and Drug Administration (FDA)."It is critical to ...
-
Trends in Biotechnology: Acquisitions, regulations and "Pink Biotech"
(11/17/2006)
Results from the panel discussions at BIO-Europe 2006
One of the most important questions, discussed on the BIO-Europe 2006, was, if major acquisitions is an indicative trend. The number of significant pharma acquisitions of biotech companies, over the year, is pointing to a new relationship between ...
|
|
|
|
|
Top